The dire situation surrounding organ transplants cannot be overstated; with approximately 120,000 individuals on waiting lists and only 45,000 transplants taking place annually, the need for efficient and reliable solutions is pressing. To mitigate these challenges, the Rice team is focused on bioprinting vascularized kidney tissues that can enhance renal function, especially for patients grappling with kidney illnesses. The tissues will be created using a bioink derived from the patients’ own cells, ensuring a compatibility that is vital for long-term success and functionality.

A noteworthy aspect of this endeavor is the central role of bioinks, as highlighted by postdoctoral researcher Vasiliki Kolliopoulos. These 3D printable inks must possess the capacity to mimic the natural tissue environment, which is essential for sustaining cellular health during the cultivation phase leading up to their implantation. The intricate development of these bioinks represents a significant scientific challenge, as they must not only support the cells but also facilitate the vascularization process—a crucial element that will determine the longevity and efficiency of the bioprinted tissues within the human body.

This research taps into the extensive expertise already established by Dr. Mikos and his team at the Biomaterials Lab at Rice University, a facility renowned for its significant contributions to the field of biomaterials and regenerative medicine. The overarching goal is to create a robust library of bioinks that can be customized to cater to the unique needs of different patients, thereby making personalized medicine a viable reality.

The funding for this innovative project comes through ARPA-H’s Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) program, which seeks to harness cutting-edge bioprinting technologies to fabricate human organs in a timely and efficient manner, eliminating the need for immunosuppressive drugs. This approach heralds a new era in organ transplantation, aiming to address not only the shortage of available organs but also associated risks that often complicate patient outcomes.

With current transplant procedures, many patients are required to take immunosuppressive medications for life, which can lead to severe complications and reduce the effectiveness of the transplant over time. This grant provides an opportunity to potentially eradicate such complications by designing organs that the body can accept without the need for ongoing medication. The promise of bioprinted organs designed with a patient’s own cells has the potential to transform not just kidney transplantation but also the field of organ donation as a whole.

Engagement with institutions such as the Wake Forest Institute for Regenerative Medicine, the University of Maryland, and collaboration with companies like PrintBio Inc. illuminates the collective effort behind this worthwhile cause. Interdisciplinary collaboration is essential to address the complex interplay of biology and technology that underlies successful tissue engineering.

Dr. Mikos underscored the importance of converging expertise from multiple domains to tackle the pressing healthcare challenge of kidney disease. There is a clear recognition that significant breakthroughs in cell manufacturing, innovative bioreactor designs, and advancements in bioprinting technology are all crucial components that will determine the success of this transformative project.

As the Rice University team forges ahead, plans are also in place to establish a scalable pathway for the commercial production and distribution of these personalized bioprinted organs. The implications of such advancements could shift the paradigm of transplantation, presenting opportunities to decrease wait times and create a more sustainable supply of organs. Additionally, if successful, the technologys principles could be adaptable for a broader range of organs, prompting researchers to envision a future with bioprinted solutions for heart, liver, and other critical organ failures.

The insights gained from this pioneering project could dramatically alter public health landscapes, offering hope to countless individuals whose quality of life has been diminished by organ failure or chronic disease. The innovations delivered through this initiative will go beyond just addressing the immediate organ shortage crisis—they could reshape the future of transplant medicine and fundamentally change how healthcare systems manage organ donation and transplantation.

In summary, the collaboration between Rice University and its partners exemplifies a potential turning point in bioprinting and regenerative medicine, showcasing how scientific rigor, creativity, and resourcefulness can come together to meet pressing medical needs. Enthusiasm among the researchers highlights a commitment to this initiative as they strive toward breakthroughs that promise not just to improve individual patients’ lives but to redefine outcomes in the field of organ transplantation globally.

Subject of Research: Bioprinting Kidney Tissues
Article Title: Revolutionary Bioprinting Project to Address Organ Donor Shortage
News Publication Date: February 6, 2026
Web References: Rice University News
References: Information from the press release issued by Rice University
Image Credits: Credit: Rice University

Keywords

• Kidney
• Bioengineering
• Biomedical Engineering
• Biomaterials
• Medical Technology
• Regenerative Medicine
• Tissue Engineering

Graphene, a single layer of carbon atoms arranged in a two-dimensional lattice, is celebrated for its exceptional strength, electrical conductivity, and thermal properties. These unique features make it an excellent candidate for improving the performance of various materials in demanding conditions, including those found in internal combustion engines. By enhancing Honge biodiesel with graphene, researchers aimed to reduce wear and tear on engine components, thereby increasing their lifespan and efficiency.

Honge oil, derived from the seeds of the Pongamia pinnata tree, is a biodiesel source known for its renewable attributes and lower environmental impacts compared to conventional petroleum. However, like many biodiesels, the performance of Honge can suffer from various limitations, including lower energy content and stability issues at high temperatures. The incorporation of graphene could potentially mitigate these drawbacks, leading to a fuel that not only meets but exceeds current performance benchmarks.

During the study, the researchers subjected engine components to rigorous testing under different operational conditions. The performance metrics included parameters such as lubricity, wear rate, and overall endurance when using pure Honge biodiesel versus its graphene-enhanced counterpart. The results were striking, showcasing that the graphene-modified fuel provided superior protection for metal surfaces and reduced friction significantly.

One of the highlights of their findings was that the graphene-enhanced biodiesel maintained greater viscosity stability, crucial for performance consistency in real-world applications. This stability translated into less sludge formation, ensuring cleaner engine operation and reduced maintenance costs over time. Moreover, the addition of graphene bolstered the thermal stability of the fuel, which is particularly advantageous given the high temperatures experienced in CI engines.

Equally important was the study’s examination of wear patterns on engine components subjected to both fuel variants. Microscopic analyses revealed that parts exposed to graphene-enhanced Honge biodiesel exhibited much less abrasive wear, a key indicator for longevity. This resilience could offer manufacturers and consumers alike an opportunity to rethink fuel choices in favor of more sustainable and efficient options.

The environmental implications of using a graphene-biodiesel blend are profound. By enhancing a renewable fuel, researchers not only contribute to reducing carbon footprints but also align with global goals to minimize reliance on fossil fuels. Biodiesel consumption, particularly when derived from waste sources or non-food crops like the Pongamia tree, presents an eco-friendly alternative while supporting local economies and reducing waste.

Furthermore, the use of graphene in biodiesel suggests a broader application of nanotechnology within the fuel sector. As researchers continue to explore nanomaterials, the potential for enhanced fuels may open new avenues for creating more efficient energy solutions across various industries. If proven successful, this treatment could be extended to other biofuels, fostering a transition to sustainable energy paradigms.

In terms of cost, one of the concerns surrounding the use of graphene has been its production. However, as the markets for graphene continue to grow and technologies to synthesize it become more accessible, the potential for cost-effective integration into fuel products also becomes increasingly viable. This shift could lead to widespread acceptance of graphene-enhanced biofuels on a commercial scale.

As we stand on the precipice of what could be a significant breakthrough in fuel technology, the implications of this research extend beyond engines and emissions. The evolution of biobased fuels is positioned at the intersection of technology, sustainability, and performance efficiency. The successful implementation of graphene-enhanced fuels could herald a new era in automotive technology where sustainability does not come at the cost of power or reliability.

Continued research into various aspects of this innovation will be paramount in validating the performance benefits observed in initial studies. Comprehensive field tests on extensive fleets of diesel vehicles are essential to confirm the real-world applicability and economic benefits of using graphene-enhanced Honge biodiesel.

Synthesizing current findings with abundant future research opportunities suggests a field ripe for exploration. Engineers and scientists are urged to collaborate across disciplines, leveraging expertise in materials science, engine design, and sustainable practices to refine and scale this breakthrough technology.

The future of transportation fuels could very well be shaped by the application of advanced materials like graphene. As scientific understanding deepens, we stand to benefit from a harmonization of technology and ecology—where improved performance aligns with environmental stewardship, steering us towards a sustainable tomorrow.

In summary, the research led by Kumar and team is a significant step towards unlocking the full potential of biodiesel through advanced materials. With ongoing investigation and collaboration, the dream of sustainable, high-performance fuels could soon become a reality widely adopted in the automotive sector.

Subject of Research: Durability impact of graphene-enhanced Honge biodiesel on CI engine components

Article Title: Durability impact of graphene-enhanced Honge biodiesel on CI engine components

Article References:

Kumar, K.S.S., Rajashekhar, C.R., Ramyarani, H.V. et al. Durability impact of graphene-enhanced Honge biodiesel on CI engine components.
Discov Sustain (2025). https://doi.org/10.1007/s43621-025-02055-2

Image Credits: AI Generated

DOI:

Keywords: Graphene, Honge biodiesel, Compression ignition engine, Durability, Sustainable fuels, Nanotechnology, Environmental impact, Performance enhancement.

Immunotherapy has emerged as a powerhouse in the fight against highly aggressive cancers and other immune-related disorders. However, the clinical benefit of such therapies varies widely among patients, driven in part by the need for robust, rapid, and multiplexed assays to concurrently monitor multiple biomarkers indicative of immune response and tumor dynamics. To meet this unmet challenge, the researchers engineered an advanced DNA hydrogel system capable of simultaneous dual-target detection, marking a paradigm shift in how immune efficacy can be quantified in real-time.

The central innovation resides in the self-assembly of DNA strands into hydrogel matrices that are exquisitely sensitive to specific biomolecular signals linked to immunotherapy targets. These hydrogels demonstrate dual-responsive functionality, meaning the matrix structure can dynamically undergo conformational changes or disintegrate upon recognizing two distinct molecular signatures. This sophisticated response mechanism not only amplifies detection accuracy but drastically reduces sample complexity by enabling multiplex analysis within a single assay environment.

The strategic use of DNA as the fundamental building block facilitates ultra-fine tuning of the hydrogel’s physicochemical properties. By encoding complementary sequences for key immune markers within the DNA network, the hydrogel exhibits outstanding specificity and binding affinity to targets such as programmed death-ligand 1 (PD-L1) and interferon-gamma (IFN-γ), which are pivotal in orchestrating immune modulation during therapy. This dual-target approach ensures comprehensive data acquisition on the immune status of a patient, empowering clinicians with actionable insights.

A defining feature of this assay lies in its simplicity and rapid turnaround time. Unlike conventional immunoassays requiring labor-intensive protocols and large reagent volumes, the DNA hydrogel system operates under mild conditions, yielding visually discernible results within minutes. This operational efficiency, combined with its multiplexed format, may significantly accelerate the clinical decision-making process, enabling real-time monitoring and timely adjustments to therapeutic regimens.

The researchers meticulously demonstrated the assay’s robustness through a series of validation experiments involving clinical samples from cancer patients undergoing immunotherapy. Results confirmed high sensitivity and reproducibility, with the assay successfully detecting fluctuations in immunotherapy biomarkers correlating with therapeutic outcomes. These findings underscore the platform’s potential to serve not only as an early predictor of treatment response but also as a tool for longitudinal patient monitoring.

Importantly, the versatility of the DNA hydrogel assay transcends cancer immunotherapy. Given its modular design, the system can be readily adapted to target a broad spectrum of biomarkers associated with various infectious diseases, autoimmune disorders, and even neurological conditions. This adaptability opens expansive avenues for future research and clinical applications, highlighting DNA hydrogels as a versatile platform in precision diagnostics.

The technology also addresses key limitations inherent in current biomarker detection methodologies, such as limited multiplexing capacity, high false-positive rates, and the need for bulky instrumentation. The compact and cost-effective nature of DNA hydrogels poised for integration with point-of-care devices could democratize access to cutting-edge diagnostics, particularly in resource-limited settings where rapid, accurate testing remains a critical bottleneck.

Additionally, the biocompatibility and biodegradability of DNA hydrogels ensure minimal toxicity and environmental impact, factors increasingly prioritized in next-generation biomedical materials. This eco-friendly profile aligns with the growing global imperative toward sustainable healthcare solutions without compromising efficacy or safety.

From a mechanistic standpoint, the assay leverages intricate molecular recognition events encoded within the nucleic acid sequences, triggering hydrogel disassembly upon target engagement. This disassembly is quantifiable via fluorescence, turbidity, or colorimetric readouts, customizable according to specific clinical requirements. The multiplex readouts facilitate a holistic understanding of the immune milieu, offering a multidimensional perspective often unattainable through single-analyte assays.

The development of this multiplexed DNA hydrogel assay exemplifies a broader trend toward integrating synthetic biology tools with advanced materials science to devise smart diagnostic systems. These systems not only perform complex analytical tasks but do so autonomously, reducing human error and enhancing reproducibility — attributes indispensable in clinical and translational research environments.

Looking ahead, optimization efforts are underway to miniaturize the assay format further, harnessing microfluidic technologies to enable ultra-high throughput screening. Such advancements would cater to large-scale clinical trials and population-wide screening programs, accelerating the pace at which novel immunotherapeutic agents can be evaluated and deployed.

The collaboration underpinning this study exemplifies interdisciplinary synergy, with contributions spanning molecular engineering, clinical oncology, and computational biology. The team envisions leveraging machine learning algorithms in tandem with assay outputs to generate predictive models of patient response, paving the way for truly personalized immunotherapy landscapes.

As immunotherapies continue to reshape oncology and beyond, technologies like this self-assembled DNA hydrogel assay represent a critical frontier for bridging laboratory innovation and bedside application. By offering a powerful new lens through which clinicians can observe and interpret immune dynamics, this approach promises to enhance treatment precision, reduce adverse effects, and ultimately improve patient survival rates.

The impact of these findings extends beyond immediate clinical utility, providing a proof-of-concept for the broader application of responsive biomaterials in healthcare. The ability to construct dynamic, programmable matrices that interface seamlessly with biological systems heralds an exciting era where diagnostic devices are not only passive detectors but active participants in the therapeutic process.

In summary, the introduction of a multiplexed assay leveraging dual-target responsive DNA hydrogels marks a transformative leap in immunotherapy monitoring. Its blend of molecular sophistication, operational simplicity, and clinical relevance positions it as a pivotal tool in the evolving arsenal against cancer and other immune-related diseases. As research progresses, this technology is expected to catalyze further innovations in biomaterial-based diagnostics, driving forward the quest for more effective, individualized patient care.

Subject of Research: Development of a multiplexed assay for immunotherapy efficacy evaluation using self-assembled dual-target responsive DNA hydrogels.

Article Title: A multiplexed assay by self-assembled dual-target responsive DNA hydrogels for efficacy evaluation of immunotherapy.

Article References:
Zhang, Y., Meng, F., Gu, Z. et al. A multiplexed assay by self-assembled dual-target responsive DNA hydrogels for efficacy evaluation of immunotherapy. Nat Commun 16, 10132 (2025). https://doi.org/10.1038/s41467-025-65075-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-65075-6

Cellular communication underpins myriad physiological processes regulating the nervous, immune, and vascular systems. Central to these communications are small signaling molecules, among which nitric oxide and ammonia play pivotal roles due to their involvement in processes like neurotransmission, immune responses, and pH regulation. However, their high chemical reactivity and gaseous, unstable nature have historically made it difficult to apply them exogenously with precision, limiting therapeutic and experimental options. The KAIST research team, led by Professor Jimin Park, has now designed a bioelectrical system that resolves these issues by generating these molecules in situ directly within the cellular microenvironment.

The newly developed platform operates by electrochemically converting a single precursor molecule, nitrite (NO₂⁻), into either nitric oxide or ammonia on demand simply by applying an electrical signal. This modular bioelectrosynthesis approach allows for dynamic modulation of the signaling output, enabling precise control over when, where, and how long specific cellular responses occur. Such spatiotemporal control is akin to flipping a molecular switch, providing a powerful tool for future applications in electroceuticals — a cutting-edge field focusing on electrical modulation of biological systems — as well as electrogenetics and personalized cell therapies.

The design of this platform draws inspiration from natural enzymatic processes involved in nitrite reduction. The team engineered catalysts with distinct metal compositions to selectively steer the electrochemical reactions toward either nitric oxide or ammonia production from the same nitrite precursor. By tailoring the catalytic environment, they developed a copper-molybdenum-sulfur complex (Cu₂MoS₄) that favors ammonia generation, contrasted with an iron-incorporated variant (FeCuMoS₄) that shifts selectivity toward nitric oxide. This careful catalyst engineering underpins the platform’s switch-like behavior.

Extensive electrochemical characterization and computational modeling revealed the mechanistic basis for product selectivity. Iron sites within the FeCuMoS₄ catalyst were found to strongly bind nitric oxide intermediate species, stabilizing these toward release as nitric oxide gas. In contrast, the Cu₂MoS₄ catalyst, lacking those iron sites, facilitates further reduction pathways that culminate in ammonia production. This precise tuning of catalytic function not only endorses the platform’s versatility but also highlights the importance of atomic-scale interactions in dictating bioelectrochemical outcomes.

To validate the biological efficacy of their system, the researchers demonstrated its capability to evoke distinct cellular responses through controlled generation of either nitric oxide or ammonia. In human cells, electrochemically produced nitric oxide was shown to activate transient receptor potential vanilloid 1 (TRPV1) channels, which are ion channels responsive to heat and various chemical stimuli and important in pain signaling pathways. Conversely, ammonia production elevated intracellular pH leading to activation of OTOP1 proton channels, which regulate proton flow and are implicated in sensory transduction.

By finely tuning the voltage applied to the catalysts and adjusting the duration of electrical stimulation, the team achieved precise temporal control over the onset and termination of these cellular signaling events. Spatial control was also demonstrated by localizing the production zones, confirming the potential of this system for highly targeted modulation necessary for complex biological interventions. This level of control effectively mimics a binary switch, turning signaling pathways on and off in living cells with high fidelity.

Professor Jimin Park emphasized the transformative potential of their work, stating that the ability to selectively generate biologically relevant signaling molecules using electrical signals opens new avenues in developing next-generation electroceutical therapies. Such therapies could target neurological disorders or metabolic diseases by precisely modifying cellular behavior without the need for invasive pharmaceuticals, reducing side effects and improving patient outcomes.

Moreover, the bioelectrosynthesis platform offers promising prospects for personalized medicine. Because electrical inputs can be precisely adjusted and tailored to an individual’s physiological needs, therapies derived from this technology may soon enable highly customized interventions, optimized not only for disease but also for unique genetic and cellular profiles. The integration of bioelectrochemical systems with cell-based therapies could revolutionize how treatments are delivered and controlled.

The study’s co-first authors, Ph.D. candidates Myeongeun Lee and Jaewoong Lee, alongside Professors Jimin Park and Jihan Kim, have set a strong precedent for interdisciplinary collaboration bridging chemical engineering, materials science, and cellular biology. Their collaborative efforts exemplify how fundamental scientific insights combined with innovative engineering can produce novel solutions to biological challenges.

This research was published in the July 8, 2025, issue of Angewandte Chemie International Edition and is now publicly accessible via DOI: 10.1002/ange.202508192. The findings underscore the expanding role bioelectrochemistry is playing in crafting new modalities for controlling living systems, heralding a future where electrical biointerfaces enable seamless modulation of life’s molecular circuitry.

As the field progresses, further optimization of catalyst design, integration with implantable devices, and expanded demonstrations in vivo will likely extend the therapeutic and research utilities of this platform. The bioelectrosynthesis approach also raises intriguing possibilities for interfacing electronics with biology at unprecedented levels of precision, fostering innovations in synthetic biology, diagnostics, and regenerative medicine.

In summary, KAIST’s bioelectrosynthesis platform marks a transformational shift in cellular modulation technologies. By leveraging electrochemical principles and advanced catalyst engineering, it overcomes previous limitations related to signaling molecule instability and spatial-temporal control. This versatile system stands poised to open new frontiers in both fundamental biological research and the development of innovative, electrically driven medical treatments targeting some of the most complex physiological systems in the human body.

Subject of Research: Bioelectrosynthesis and selective modulation of cellular signaling molecules using electrochemical platforms.

Article Title: Bioelectrosynthesis of Signaling Molecules for Selective Modulation of Cell Signaling

News Publication Date: August 11, 2025

Web References:
DOI Link to article

References:
Lee, M., Lee, J., Kim, Y., Lee, C., Oh, S.Y., Kim, J., Park, J. (2025). Bioelectrosynthesis of Signaling Molecules for Selective Modulation of Cell Signaling. Angewandte Chemie International Edition. DOI: 10.1002/ange.202508192.

Image Credits: KAIST

Keywords: bioelectrosynthesis, nitric oxide, ammonia, cellular signaling, electrochemical catalyst, electroceuticals, spatiotemporal control, TRPV1 channel, OTOP1 proton channel, nitrite reduction, Cu₂MoS₄ catalyst, FeCuMoS₄ catalyst

The innovation centers on a meticulously engineered network of flexible, biocompatible electrodes fabricated from fluorinated elastomers that match the mechanical softness of the neural tissues they monitor. Unlike rigid microelectrodes or invasive metal probes that inevitably damage cells and limit recordings to later developmental stages or mature brains, this soft mesh conforms and folds seamlessly with the brain’s evolving 3D architecture. This design enables continuous, non-disruptive monitoring across embryonic stages with millisecond temporal resolution, capturing the dynamic emergence of neural circuits in real time without impeding normal development or behavior in the tadpoles.

This breakthrough tackles a long-standing gap in neuroscience research: the inability to chronically measure brain activity during the earliest phases of neural differentiation and morphogenesis. Diseases such as autism spectrum disorders, schizophrenia, and bipolar disorder have been hypothesized to originate in these critical early windows, yet understanding their biological underpinnings has been limited by technological constraints. Jia Liu, Assistant Professor of Bioengineering at Harvard SEAS and senior author of the study, emphasized the technology’s potential to unlock these previously inaccessible neurodevelopmental stages, stating, “There is just no ability currently to measure neural activity during early neural development. Our technology will really enable an uncharted area.”

The neural plate is a transient, flat cellular sheet that undergoes rapid folding and intricate morphological transformations on millisecond timescales, eventually forming the neural tube—the embryonic structure that becomes the brain and spinal cord. Capturing electrical signals during this critical sequence demands bioelectronic devices that are not only ultra-soft and dynamically stretchable but also highly resilient to withstand fabrication processes and maintain functional integrity throughout growth. The team’s integration of perfluoropolyether-dimethacrylate fluorinated elastomers, a newly developed material combining softness with electronic durability, was instrumental in meeting these stringent requirements.

Previous attempts at brain interfacing have relied primarily on metal electrodes or patch-clamp techniques applied to mature nervous systems. While electrode arrays embedded in stem cell-derived organoids have shown promise, their relative mechanical stiffness compared to amphibian embryos presented significant challenges. Tadpole embryos, being orders of magnitude softer and more pliable than engineered organoid tissues, forced Liu’s team to rethink material properties, device geometry, and implantation strategies comprehensively. This comprehensive approach yielded an electronic mesh that physically matches and integrates with embryonic tissue, thus avoiding the neuronal damage traditionally caused by probe insertion.

This soft mesh electronics platform embodies a paradigm shift in brain-machine interface technology. By “leveraging the natural development process,” as Liu describes, it becomes possible to deploy arrays of sensors distributed throughout the emerging 3D brain architecture noninvasively. This unlocks previously unattainable longitudinal studies of how neural activity patterns evolve alongside anatomical growth and differentiation, promising unprecedented insights into integrative neuroscience, neural stem cell biology, and disease progression. According to the researchers, this capability marks the first successful translation of soft, stretchable bioelectronics from organoids to living vertebrate embryos.

The research builds on years of advances in flexible, tissue-like microelectronics pioneered by Liu’s lab. Their prior work demonstrated embedding these devices into cardiac and brain organoids, creating “cyborg” tissue models that replicate aspects of in vivo physiology. Extending these ideas to living tadpole embryos, however, demanded substantial innovation in materials science and engineering. The custom fluorinated elastomers employed here possess unique combinations of elasticity, chemical inertness, and compatibility with nanofabrication methods, enabling high-density electrode arrays that maintain fine spatial resolution across dynamic warping of biological tissue.

Beyond fundamental neuroscience, the technological platform has far-reaching implications for biomedical engineering and translational medicine. For example, two-dimensional soft bioelectronics could be scaled into next-generation brain-machine interfaces to monitor or stimulate neural activity in developmental disorders, traumatic injuries, or neurodegeneration. The intellectual property for these fluorinated elastomer materials has been protected through Harvard’s Office of Technology Development, which licensed the technology to Axoft, a startup co-founded by Liu. Axoft focuses on scalable, soft bioelectronic systems that may one day facilitate seamless human-computer integration or targeted therapeutics with minimal invasiveness.

The study, published in the journal Nature, represents a collaborative effort involving a multidisciplinary team of bioengineers, neuroscientists, and materials scientists. Key contributions came from postdoctoral fellow Hao Sheng and co-authors who refined device fabrication, tested in vivo biocompatibility, and performed electrophysiological measurements using the implanted sensors. Financial support was provided by significant federal grants from the National Institutes of Health and the National Science Foundation, underscoring the potential impact and innovative character of this project.

This achievement signals a new chapter in the study of developmental neuroscience, allowing direct observation of electrical signaling during primary brain formation in a living vertebrate embryo. The process of neurogenesis, neural tube formation, and circuitry assembly can now be monitored with unprecedented spatial and temporal granularity. Such data will be invaluable in decoding the earliest patterns of neural connectivity that underpin cognition, behavior, and disease susceptibility.

In summary, Harvard’s soft bioelectronic mesh represents a transformative technology poised to redefine how scientists study the origins of brain function and dysfunction. Its seamless integration into embryonic nervous tissue demonstrates that softness, stretchability, and resilience can coexist in a device capable of recording the brain’s earliest electrical impulses. This innovation not only offers hope for enhanced understanding and treatment of neurodevelopmental disorders but also charts a path toward sophisticated brain-machine interfaces imbedded naturally within the nervous system.

Subject of Research: Animal tissue samples

Article Title: Brain implantation of soft bioelectronics via embryonic development

News Publication Date: 11-Jun-2025

Web References:
https://dx.doi.org/10.1038/s41586-025-09106-8

References:
Liu, J. et al. Brain implantation of soft bioelectronics via embryonic development. Nature. DOI: 10.1038/s41586-025-09106-8

Image Credits: Liu Lab / Harvard SEAS

Keywords: Brain development, Neural stem cells, Neural tube, Neurogenesis, Neurochemistry, Neuroimaging, Organismal biology, Animals, Physical sciences, Materials science, Materials engineering, Materials, Polymers, Biomaterials, Integrative neuroscience, Microbiology, Developmental biology, Applied sciences and engineering, Engineering, Bioengineering, Biotechnology, Bioelectronics, Electronics, Electronic devices

Mikos’s pioneering work bridges fundamental biomaterials science with translational applications in medicine. His research portfolio spans sophisticated strategies for developing biocompatible scaffolds that mimic the extracellular matrix, enabling the regeneration of complex tissues. He has extensively explored synthetic and natural polymer systems tailored to degrade at controlled rates, releasing therapeutic agents in a spatiotemporally regulated manner. These innovations have had far-reaching implications in orthopedic, dental, cardiovascular, neurologic, and ophthalmologic medicine, advancing patient-specific regenerative solutions.

Central to Mikos’s research is the design of multifunctional biomaterials capable of interfacing with biological systems to promote healing and regeneration. His work delves into the intricate signaling pathways involved in tissue repair, leveraging biomaterial chemistry to orchestrate cellular responses. A notable focus is on gene-activated matrices that facilitate localized gene therapy, invigorating endogenous repair mechanisms. This nexus of biomaterials and gene therapy presents a frontier for precision medicine, combining material science with molecular biology.

The engineering of three-dimensional tissue constructs remains a cornerstone of Mikos’s contributions. His laboratory champions the use of porous scaffolds that support cell attachment, proliferation, and differentiation while enabling nutrient diffusion. These structures serve as models for studying disease progression and therapeutic interventions. By integrating microfabrication techniques and bioreactors, Mikos’s team replicates physiological environments to enhance tissue maturation ex vivo, thereby advancing organ repair and replacement paradigms.

Regulated drug delivery systems developed under Mikos’s guidance have reshaped treatment approaches for chronic diseases. These biomaterials provide sustained release profiles, reducing systemic toxicity while maximizing therapeutic efficacy. Customizable delivery vehicles, from hydrogels to nanoparticles, have been engineered to respond to environmental stimuli such as pH and enzymatic activity. Such responsiveness allows for on-demand drug release, optimizing timing and dosage to patient needs.

Mikos’s interdisciplinary collaborations stretch across biomedical engineering, material science, and clinical medicine, underscoring his commitment to translational research. His work not only elucidates foundational principles but also accelerates the path from bench to bedside. The impact of his biomaterials is evident in clinical trials targeting bone regeneration and cartilage repair, including strategies that combat inflammation and infection at injury sites.

Beyond his research achievements, Mikos plays a vital role in shaping the scientific community. As founding editor and editor-in-chief of the Tissue Engineering journals, he has cultivated a platform accelerating discoveries and cross-disciplinary dialogue. Mentorship is a hallmark of his career, fostering a generation of researchers who continue to innovate in regenerative medicine and bioengineering worldwide.

His election to the European Academy of Sciences affirms his status as a global leader whose work transcends national boundaries. The academy’s emphasis on interdisciplinary collaboration and societal impact resonates deeply with Mikos’s vision. He anticipates that membership will augment opportunities to exchange knowledge and contribute to international efforts that harness science and technology for human betterment.

At Rice University, Mikos directs multiple research hubs including the Biomaterials Lab, the Center for Excellence in Tissue Engineering, and the J.W. Cox Laboratory for Biomedical Engineering. These centers epitomize a convergence of basic science and engineering with clinical application, fostering environments where innovative biomaterials evolve from concept to clinical reality. His membership in the National Academy of Engineering, the National Academy of Medicine, and other esteemed societies further underscores his profound influence.

With an impressive publication record exceeding 700 scientific articles and over 30 patented technologies, Mikos’s contributions illustrate an extraordinary blend of creativity and rigor. His research continues to push the boundaries of how engineered biomaterials can emulate and augment biological functions. The widespread clinical adoption of his innovations reflects a transformative impact that extends well beyond academic circles.

The formal induction ceremony for Mikos’s inclusion into the European Academy of Sciences will take place on December 17-18, 2025, during the EURASC Annual Symposium at CERN in Geneva. This event not only honors his past achievements but also heralds new opportunities for advancing collaborative research across continents. Mikos expressed his eagerness to engage with this distinguished community to drive forward the frontiers of knowledge.

The recognition of Antonios Mikos’s accomplishments highlights the essential role of biomaterials science in medicine’s future. As challenges such as organ shortages and chronic disease burdens grow, his work illuminates pathways to engineered solutions capable of repairing and regenerating damaged tissues. Mikos’s visionary approach exemplifies the potency of integrating engineering principles with biological insight to revolutionize healthcare.

Through continuous innovation and leadership, Mikos remains at the forefront of efforts to harness the potential of materials science in healing the human body. His election to the European Academy of Sciences cements a legacy marked by transformative advances, global collaboration, and a steadfast commitment to improving lives through science and engineering.

Subject of Research: Biomaterials and Tissue Engineering in Regenerative Medicine and Controlled Drug Delivery

Article Title: Antonios Mikos Elected to European Academy of Sciences for Pioneering Advances in Biomaterials and Regenerative Medicine

News Publication Date: May 19, 2025

Web References: https://news.rice.edu/

Image Credits: Photo by Gustavo Raskosky/Rice University

Keywords: Regenerative medicine, Tissue engineering, Bioengineering, Engineering, Biomaterials

This innovative delivery system capitalizes on the intrinsic biocompatibility and modularity of elastin-like polypeptides, which mimic the resilience and versatility of natural elastin. Through a meticulous iterative design process, the team engineered fourth-generation ELPs covalently fused with strategically selected cationic endosomal escape peptides (EEPs). These specialized peptides dynamically respond to the acidic milieu of endosomes, triggering conformational changes that facilitate the destabilization of endosomal membranes, thereby enabling the cargo payload to breach into the cytosol intact and functional.

Central to the development of this platform was a comprehensive in silico screening campaign of thousands of α-helical peptide candidates. Utilizing advanced computational modeling and peptide structure-function predictions, the researchers identified a particularly potent EEP, designated EEP13, which demonstrated a remarkable 48% enhancement in protein delivery efficiency over established benchmark peptides. This computational approach underscores the power of integrating bioinformatics with synthetic biology to expedite the identification of functional peptide motifs with superior performance.

ENTER’s novel self-assembling architecture results in nanoparticles that respond to the subtle pH gradients encountered during endosomal maturation. Upon cellular uptake, these nanoparticles capitalize on the transition from a neutral extracellular environment to increasingly acidic endosomal compartments, prompting their micellar structure to disassemble and expose the embedded EEP domains. This exposure triggers membrane disruption events finely tuned to minimize nonspecific cytotoxicity—a significant improvement over conventional cationic lipid-based delivery systems known for their inflammatory and cell-viability liabilities.

The therapeutic versatility of ENTER was rigorously tested across a broad spectrum of biomolecular cargoes, including mRNA-encoded proteins, plasmid DNA, purified proteins, and short interfering RNAs (siRNAs). The platform excelled in intracellular delivery efficiency and functional activity in multiple immortalized cell lines as well as challenging primary cell types that typically resist transfection. Notably, the delivery of Cre recombinase—an enzyme widely utilized in genomic editing scenarios—was achieved with efficiency comparable to, or surpassing, commercial lipid reagents, thus validating the system’s translational potential for gene therapy applications.

In addition to in vitro demonstrations, ENTER’s performance was corroborated in vivo through intranasal administration in reporter mouse models. The nanoparticle system successfully mediated precise genomic editing within lung epithelial cells—a tissue traditionally difficult to target—by effective delivery of Cre protein. This result highlights the promise of ENTER for non-invasive therapeutic interventions in pulmonary diseases and epitomizes how protein-based nanoparticle formulations can circumvent the limitations of viral vectors and lipid nanoparticles, especially for mucosal tissue targeting.

Technically, the ELP backbone provides a highly tunable scaffold, allowing precise control over nanoparticle size, surface charge, and stability by adjusting polypeptide length and fusion motifs. This modularity enables the customization of delivery vehicles tailored to specific cargo types and therapeutic contexts. Moreover, the EEP domains are designed to adopt stable α-helical conformations that facilitate membrane interaction, a property systematically optimized through computational peptide design to balance potency with biocompatibility.

Compared to conventional delivery platforms, ENTER offers a robust safety profile, minimizing adverse effects commonly associated with cationic lipids and viral vectors such as immunogenicity, off-target interactions, and payload degradation. The self-assembling nature of these nanoparticles reduces the necessity for complex chemical formulations or toxic solvents, paving the way for streamlined manufacturing and scalability, essential features for clinical translation.

The significance of this discovery extends beyond immediate therapeutic applications. It also provides a versatile platform for basic biomedical research, enabling more efficient intracellular delivery of genome editors such as CRISPR-Cas systems, thereby expediting functional genomics studies and drug discovery pipelines. The combinatorial approach of machine learning-guided peptide design and protein engineering embodied by ENTER exemplifies a forward-thinking paradigm in nanoparticle therapeutics.

Furthermore, the intranasal delivery modality explored in vivo opens exciting avenues for treating respiratory illnesses through direct targeting of lung epithelial tissues. Diseases such as cystic fibrosis, chronic obstructive pulmonary disease, and viral infections could potentially benefit from this innovative technology by facilitating localized and controlled therapeutic payload release without systemic exposure.

This landmark study also underscores the growing importance of biomimetic and stimuli-responsive materials in drug delivery. By leveraging the elastic properties and environmental responsiveness of elastin-like sequences, the researchers demonstrated how bioinspired polymers can recapitulate nature’s sophisticated mechanisms for cellular entry and intracellular trafficking, overcoming classical bottlenecks that have plagued the field for decades.

While the current results are highly promising, further investigations will likely focus on long-term biocompatibility, biodistribution, and immunological profiling in larger animal models. Additionally, tailoring the platform for targeted delivery to diverse cell types and organs through surface modification or ligand conjugation could further enhance its therapeutic versatility.

In conclusion, the advent of ENTER represents a transformative step forward in protein-based nanomedicine, offering a novel, safe, and efficient system for the cytosolic delivery of a wide array of therapeutic biomacromolecules. This leap is poised to accelerate the pace at which gene editing and biomolecular therapies transition from bench to bedside, heralding a new era of precision medicine with broad-reaching impacts across genetic, infectious, and inflammatory diseases.

—–

Subject of Research: Development of recombinant elastin-like polypeptide-based nanoparticles for efficient cytosolic delivery of nucleic acids and proteins.

Article Title: Self-assembling protein nanoparticles for cytosolic delivery of nucleic acids and proteins.

Article References:
Eweje, F., Ibrahim, V., Shajii, A. et al. Self-assembling protein nanoparticles for cytosolic delivery of nucleic acids and proteins. Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02664-2

Image Credits: AI Generated